Newstral
Article
jdsupra.com on 2016-11-17 21:35
Amgen and Allergan Submit BLA for Avastin® Biosimilar
Related news
- Amgen and Allergan Submit European Application for Avastin® Biosimilarjdsupra.com
- MAmgen and Allergan say FDA has approved biosimilar of Roche's Avastinmarketwatch.com
- Genentech Files DJ Action Against Amgen Regarding Avastin Biosimilarjdsupra.com
- Amgen and Genentech Break New Ground in Avastin Biosimilar Disputejdsupra.com
- Amgen Reports on Neulasta, Neupogen Biosimilar Competition and Acceptance of Avastin Biosimilar aBLAjdsupra.com
- Amgen and Allergan Report Progress in Herceptin® Biosimilar Clinical Trialjdsupra.com
- FDA Approves First Avastin Biosimilarjdsupra.com
- UBevacizumab Biosimilar Market 2021 Share, Size, Future Demand, Trends, Region by Forecast to 2027| Pfizer, Allergan, Amgen, Bioconunlvrebelyell.com
- FDA Approves Amgen’s Biosimilar of Avastin®jdsupra.com
- Will The Avastin Biosimilar Patent Dance Go On?jdsupra.com
- PAmgen asks FDA to approve biosimilar drugpacbiztimes.com
- Boehringer Ingelheim Announces Phase I Results for Avastin® Biosimilarjdsupra.com
- PFDA approves Amgen biosimilar of AbbVie’s Humirapacbiztimes.com
- PFDA approves Amgen cancer treatment biosimilar Mvasipacbiztimes.com
- PGenentech sues Amgen over biosimilar drug infopacbiztimes.com
- A Global Phase III Trial for Avastin Biosimilar Has Begunjdsupra.com
- Pfizer Receives European Approval For Avastin® (Bevacizumab) Biosimilarjdsupra.com
- PAmgen settles with AbbVie over Humira biosimilarpacbiztimes.com
- Amgen Sues Pfizer Over Proposed Neulasta Biosimilarjdsupra.com
- Amgen Releases 2022 Biosimilar Trends Reportjdsupra.com